CMC Biologics, a contract manufacturing organization known for its in process development and cGMP manufacture capabilities, today announced the acquisition of XOMA Corporation’s, large-scale manufacturing operations and affiliated assets located in Berkeley, California. Financial terms of the transaction were not disclosed.
“We are very pleased to expand our clinical and commercial manufacturing operations to one of largest and most robust biotechnology clusters in the world,” said Claes Glassell, Chief Executive Officer of CMC Biologics. “Establishing a facility in the Bay Area complements our existing facilities located in Bothell, Washington and in Copenhagen Denmark, and supports our continued growth and addresses the growing demand of our customers for cGMP clinical and commercial production of biopharmaceuticals.” The fully functional 31,000 square foot facility is a completely equipped biological manufacturing operation, including three 2750L stainless steel bioreactors and two purification suites, as well as warehouse and office space. CMC Biologics expects to begin offering contract manufacturing services from this location immediately following the close of the transaction.
In June, CMC Biologics received Certificate of Good Manufacturing Practice (GMP) Compliance for commercial manufacturing issued by the Medicines and Healthcare products Regulatory Agency (MHRA). CMC Biologics’ commitment to compliance and high quality systems resulted in the success of this important regulatory milestone and demonstrates excellence in the Company’s manufacturing, process, and quality systems.
